Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew T Hueman

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Military Medicine|January 27, 2021
Clinical Readiness Program: Refocusing the Military Health SystemDanielle B Holt, Matthew T Hueman, Jonathan Jaffin, et al.
Oncology Reports|February 3, 2007
Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex technologyZia A Dehqanzada, Catherine E Storrer, Matthew T Hueman, et al.
Surgery|December 7, 2016
Nonsteroidal anti-inflammatory drugs may affect cytokine response and benefit healing of combat-related extremity woundsFelipe A Lisboa, Matthew J Bradley, Matthew T Hueman, et al.
Journal of the American College of Surgeons|February 2, 2010
Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trialRitesh Patil, Guy T Clifton, Jarrod P Holmes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2005
Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patientsGeorge E Peoples, Jennifer M Gurney, Matthew T Hueman, et al.
Cancer|August 30, 2008
Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02Jarrod P Holmes, Jeremy D Gates, Linda C Benavides, et al.
International Journal of Oncology|November 18, 2004
Preclinical testing of a peptide-based, HER2/neu vaccine for prostate cancerMichael M Woll, Matthew T Hueman, Gayle B Ryan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2006
Correlations between serum monocyte chemotactic protein-1 levels, clinical prognostic factors, and HER-2/neu vaccine-related immunity in breast cancer patientsZia A Dehqanzada, Catherine E Storrer, Matthew T Hueman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2009
The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02Linda C Benavides, Jeremy D Gates, Mark G Carmichael, et al.
Journal of the American College of Surgeons|February 21, 2009
Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patientsJeremy D Gates, Mark G Carmichael, Linda C Benavides, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Military Medicine|January 27, 2021
Clinical Readiness Program: Refocusing the Military Health SystemDanielle B Holt, Matthew T Hueman, Jonathan Jaffin, et al.
Oncology Reports|February 3, 2007
Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex technologyZia A Dehqanzada, Catherine E Storrer, Matthew T Hueman, et al.
Surgery|December 7, 2016
Nonsteroidal anti-inflammatory drugs may affect cytokine response and benefit healing of combat-related extremity woundsFelipe A Lisboa, Matthew J Bradley, Matthew T Hueman, et al.
Journal of the American College of Surgeons|February 2, 2010
Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trialRitesh Patil, Guy T Clifton, Jarrod P Holmes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2005
Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patientsGeorge E Peoples, Jennifer M Gurney, Matthew T Hueman, et al.
Cancer|August 30, 2008
Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02Jarrod P Holmes, Jeremy D Gates, Linda C Benavides, et al.
International Journal of Oncology|November 18, 2004
Preclinical testing of a peptide-based, HER2/neu vaccine for prostate cancerMichael M Woll, Matthew T Hueman, Gayle B Ryan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2006
Correlations between serum monocyte chemotactic protein-1 levels, clinical prognostic factors, and HER-2/neu vaccine-related immunity in breast cancer patientsZia A Dehqanzada, Catherine E Storrer, Matthew T Hueman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2009
The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02Linda C Benavides, Jeremy D Gates, Mark G Carmichael, et al.
Journal of the American College of Surgeons|February 21, 2009
Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patientsJeremy D Gates, Mark G Carmichael, Linda C Benavides, et al.
Pageof 4